Analisis Faktor yang Berhubungan dengan Potensi Interaksi Obat Pasien Covid-19 di Salah Satu Rumah Sakit Kalimantan Selatan
Factors Associated with Potential Drug Interactions in Covid-19 Hospitalized Patients
DOI:
https://doi.org/10.25026/jsk.v5i5.1811Abstract
Patients with COVID-19 are treated with antivirals, supportive therapy, and symptomatic therapy. COVID-19 patients who use multiple drugs may experience drug interactions. The purpose of this study is to investigate factors associated with potential drug interactions in COVID-19 patients who are hospitalized. This cross-sectional retrospective observational study was carried out in a hospital in the Indonesia. The sample consists of medical records from COVID-19 patients who received therapy and were hospitalized between January and March 2021. The IBM Micromedex website, DrugBank Interaction Checker, and Stockley Drug Interactions 9th Edition are research tools used to assess the potential and mechanism of drug interactions. The results were 82 medical records that were analyzed for potential drug interactions. The proportion of patients who have potential drug interactions is 69.5%. in hospitalized COVID-19 patients. The drug interaction mechanism in COVID-19 patients is potentially in the pharmacokinetics phase. Age (p=0.034; OR 0.327, CI 0.11-0.94), number of drugs used during treatment (p=0.002; OR 14.00, CI 1.76-111.11), and length of stay (p=0.000; OR 0.009, CI 0.001-0.07) were factors associated to potential drug interactions. Subsequently, factors associated with potential drug interactions in COVID-19 hospitalized patients include age, number of drugs used during treatment, and length of stay.
Keywords: COVID-19, drug interactions, factors associated, potential
Abstrak
Tatalaksana pengobatan pada pasien COVID-19 diberikan antivirus, terapi suportif dan terapi simptomatik. Penggunaan beberapa jenis obat tersebut membuat pasien COVID-19 berpotensi mengalami interaksi obat. Penelitian ini bertujuan menganalisis faktor yang berhubungan dengan potensi interaksi obat pada pasien COVID-19 rawat inap di rumah sakit. Penelitian obeservasional retrospektif cross sectional ini dilaksanakan di salah satu rumah sakit Kalimantan Selatan. Sampel yakni rekam medis pasien COVID-19 yang mendapat terapi dan rawat inap di rumah sakit periode Januari-Maret 2021 Instrumen penelitian mengkaji potensi dan mekanisme interaksi obat meliputi situs IBM Micromedex , DrugBank Interaction Checker dan Stockley Drug Interactions 9th Edition. Hasil diperoleh sebanyak 82 rekam medis dianalisis potensi interaksi obat. Persentase pasien mengalami potensi interaksi obat sebesar 69,5%. pada pasien COVID-19 rawat inap di rumah sakit. Mekanisme interaksi obat pada pada pasien COVID-19 pada berpotensi pada fase farmakokinetika. Faktor berhubungan potensi interaksi obat pasien COVID-19 yakni usia (p=0.034; OR 0.327, CI 0.11-0.94), jumlah obat yang digunakan selama dirawat (p=0.002; OR 14.00, CI 1.76-111.11) dan lama dirawat (p=0.000; OR 0.009 , CI 0.001-0.07). Kesimpulan, faktor berhubungan potensi interaksi obat pada pasien COVID-19 rawat inap di rumah sakit meliputi usia, jumlah obat yang digunakan selama dirawat dan lama dirawat.
Kata Kunci: COVID-19, faktor berhubungan, interaksi obat, potensi
References
N. Afrianti and C. Rahmiati, 2021, Faktor-Faktor yang Mempengaruhi Kepatuhan Masyarakat terhadap Protokol Kesehatan Covid-19, Jurnal Ilmiah Permas: Jurnal Ilmiah STIKES Kendal, vol. 11, no. 1, doi: 10.32583/pskm.v11i1.1045.
P. K. Manjhi, R. Kumar, A. Priya, and I. Rab, 2021, Drug-Drug Interactions in Patients with COVID-19: A Retrospective Study at a Tertiary Care Hospital in Eastern India, Maedica (Bucur), vol. 16, no. 2, pp. 163–169, doi: 10.26574/maedica.2021.16.2.163.
Y. S. Malik et al., 2020, Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective,” Pathogens, vol. 9, no. 7, p. 519, doi: 10.3390/pathogens9070519.
WHO, 2021, WHO Coronavirus Disease (COVID-19) Dashboard, https://covid19.who.int/
E. Mathieu et al., 2023,Coronavirus Pandemic (COVID-19), Our World in Data, 2020, Accessed: Jan. 11, https://ourworldindata.org/coronavirus
Z.-M. Chen et al., 2020, Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus, World J Pediatr, vol. 16, no. 3, pp. 240–246, doi: 10.1007/s12519-020-00345-5.
C. Stasi, S. Fallani, F. Voller, and C. Silvestri, 2020, Treatment for COVID-19: An overview, Eur J Pharmacol, vol. 889, p. 173644, doi: 10.1016/j.ejphar.2020.173644.
E. Burhan et al., 2020, Pedoman Tatalaksana COVID-19 Edisi Ke-3. Jakarta: PDPI, PERKI, PAPDI, PERDATIN & IDAI.
L. A. Kusumawardani, N. Maria, and Y. N. Fanani, 2021,Potential drug interactions analysis of COVID-19 patients at a hospital in West Java, JIF, vol. 17, doi: 10.20885/jif.vol17.iss2.art8.
A. Anggriani, P. Utami, and I. Lisni, 2016, Kajian Potensi Interaksi Obat Pada Pasien Glaukoma di Salah Satu Rumah Sakit di Bandung, Jurnal Sains dan Kesehatan (J. Sains Kes.), vol. 1, no. 5, doi: 10.25026/jsk.v1i5.44.
V. Conti et al., 2022, Identification of Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review, JAMA Network Open, vol. 5, no. 4, p. e227970, Apr. doi: 10.1001/jamanetworkopen.2022.7970.
D. Kumar and N. Trivedi, 2021, Disease-drug and drug-drug interaction in COVID-19: Risk and assessment, Biomedicine & Pharmacotherapy, vol. 139, p. 111642, doi: 10.1016/j.biopha.2021.111642.
S. S. Maulidia, F. Mahmudah, and Y. Sastyarina, 2021,Kajian Potensi Interaksi Obat pada Pasien COVID-19 di Rumah Sakit X Kota Samarinda: Study of Potential Drug Interactions in COVID-19 Patients at Hospital X Samarinda City, Proceeding of Mulawarman Pharmaceuticals Conferences (Proc. Mul. Pharm. Conf.), vol. 14, pp. 295–301, doi: 10.25026/mpc.v14i1.587.
A. M. P. Putra, Y. Wasiaturrahmah, and N. Rahmah, 2021, Potensi Interaksi Obat Pada Pasien COVID-19 Di Salah Satu Rumah Sakit Di Provinsi Kalimantan Selatan, Majalah Farmasi dan Farmakologi, vol. 25, no. 3, pp. 94–97.
W. Ayenew, G. Asmamaw, and A. Issa, 2020, Prevalence of potential drug-drug interactions and associated factors among outpatients and inpatients in Ethiopian hospitals: a systematic review and meta-analysis of observational studies, BMC Pharmacology and Toxicology, vol. 21, no. 1, p. 63, doi: 10.1186/s40360-020-00441-2.
M.-L. Yeh, Y.-J. Chang, P.-Y. Wang, Y.-C. J. Li, and C.-Y. Hsu, 2013, Physicians’ responses to computerized drug-drug interaction alerts for outpatients, Comput Methods Programs Biomed, vol. 111, no. 1, pp. 17–25, doi: 10.1016/j.cmpb.2013.02.006.
S. Niu et al., 2020, Clinical characteristics of older patients infected with COVID-19: A descriptive study, Archives of Gerontology and Geriatrics, vol. 89, no. April, p. 104058, doi: 10.1016/j.archger.2020.104058.
J. She, L. Liu, and W. Liu, 2020, 2020 COVID?19 epidemic Disease characteristics in children, pp. 747–754.
P. Yu, J. Zhu, Z. Zhang, and Y. Han, 2020, A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period, Journal of Infectious Diseases, vol. 221, no. 11, pp. 1757–1761, doi: 10.1093/infdis/jiaa077.
B. D. Pepitasari and T. D. Anggraini, 2021, Gambaran Tatalaksana Terapi Pada Pasien COVID-19 Terkonfirmasi di Rumah Sakit X Kota Surakarta Periode Maret – Desember 2020, Journal On Medical Science, vol. 8, no. 2, pp. 119–126.
J. M. Jin et al., 2020,Gender Differences in Patients With COVID-19: Focus on Severity and Mortality, Frontiers in Public Health, vol. 8, no. April, pp. 1–6, doi: 10.3389/fpubh.2020.00152.
R. McQueenie et al., 2020,Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort, PLoS ONE, vol. 15, no. 8 August, pp. 1–15, doi: 10.1371/journal.pone.0238091.
R. Chaliks, 2015,Factors Influence the Potential Drug Interaction Occurence among Hospitalized Patients with Cronic Kidney Disease at Labuang Baji Hospital Makassar, International Journal of Sciences: Basic and Applied Research (IJSBAR), vol. 24, no. 3.
I. Cascorbi, 2012, Arzneimittelinteraktionen: Prinzipien, Beispiele und klinische Folgen, Deutsches Arzteblatt International, vol. 109, no. 33–34, pp. 546–556, doi: 10.3238/arztebl.2012.0546.
K. Baxter, 2010, Stockley’s Drug Interactions, Ninth Edition, Pharmaceutical Press, London.
Rikomah, 2018, Farmasi Klinik, Deepublish Publisher, Yogyakarta.
Rodrigues, 2008, Drug-Drug Interaction Second Edition. Informa Healthcare USA.
Micromedex, 2021,“IBM Micromedex, https://www.micromedexsolutions.com/micromedex2/librarian/
C. Tanaka, 2014, Clinical pharmacology of deferasirox, Clinical Pharmacokinetics, vol. 53, no. 8, pp. 679–694, doi: 10.1007/s40262-014-0151-4.
Drugbank, 2022, Drug Interaction Checker, Drug Interaction Checker, https://go.drugbank.com/drug-interaction-checker
D. Sola et al., 2015, Sulfonylureas and their use in clinical practice, Archives of Medical Science, vol. 11, no. 4, pp. 840–848, doi: 10.5114/aoms.2015.53304.
M. May and C. Schindler, 2016, Clinically and pharmacologically relevant interactions of antidiabetic drugs, Therapeutic Advances in Endocrinology and Metabolism, vol. 7, no. 2, pp. 69–83, doi: 10.1177/2042018816638050.
D. R. Morales, J. Slattery, A. Pacurariu, L. Pinheiro, P. McGettigan, and X. Kurz, 2019, Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–Control Study, Clinical Drug Investigation, vol. 39, no. 2, pp. 205–213, doi: 10.1007/s40261-018-0729-y.
N. Diksis, T. Melaku, D. Assefa, and A. Tesfaye, 2019,Potential drug–drug interactions and associated factors among hospitalized cardiac patients at Jimma University Medical Center, Southwest Ethiopia, SAGE Open Med, vol. 7, p. 2050312119857353, Jun. doi: 10.1177/2050312119857353.
L. Bjerrum, B. Gonzalez Lopez-Valcarcel, and G. Petersen, 2008, Risk factors for potential drug interactions in general practice, European Journal of General Practice, vol. 14, no. 1, pp. 23–29, doi: 10.1080/13814780701815116.
L. Parulian, E. Listyanti, A. K. Hati, and I. Sunnah, 2019, Analisis Hubungan Polifarmasi Dan Interaksi Obat Pada Pasien Rawat Jalan Yang Mendapat Obat Hipertensi Di Rsp. Dr. Ario Wirawan Periode Januari-Maret 2019, Indonesian Journal of Pharmacy and Natural Product, vol. 2, no. 2.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Jurnal Sains dan Kesehatan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
